L-2′,3′-didehydro-2′,3′-dideoxy-3′- fluoronucleosides: Synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance

Journal of Medicinal Chemistry

Volumn 46, Issue 15, 2003, Pages 3245-3256

  Chong, Youhoon ^a   Gumina, Giuseppe ^a   Mathew, Judy S ^b   Schinazi, Raymond F ^b   Chu, Chung K ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIDEOXY 2,3 DIDEHYDRO 3 FLUORO BETA LEVO RIBOFURANOSYL) 5 FLUOROCYTOSINE; 1 (2,3 DIDEOXY 2,3 DIDEHYDRO 3 FLUORO BETA LEVO RIBOFURANOSYL)CYTOSINE; 1 (2,3 DIDEOXY 3,3 DIFLUORO BETA LEVO RIBOFURANOSYL) 5 FLUOROCYTOSINE; 1 (2,3 DIDEOXY 3,3 DIFLUORO BETA LEVO RIBOFURANOSYL)CYTOSINE; ANTIVIRUS AGENT; GUANOSINE; HYDROFLUORIC ACID; LAMIVUDINE; LEVO 3' FLUORO 2',3' DIDEHYDRO 2',3' DIDEOXYCYTIDINE; NUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NUCLEOSIDE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG MECHANISM; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ELIMINATION REACTION; HUMAN; HUMAN CELL; MOLECULAR MODEL; MONONUCLEAR CELL; NONHUMAN; STATISTICAL SIGNIFICANCE; STEREOCHEMISTRY; VERO CELL; ANTIBIOTIC RESISTANCE; BINDING SITE; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POINT MUTATION; STRUCTURE ACTIVITY RELATION; SYNTHESIS; VIROLOGY;

ANTI-HIV AGENTS; BINDING SITES; CELL LINE; DRUG RESISTANCE, VIRAL; DRUG STABILITY; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; HYDROGEN BONDING; LAMIVUDINE; LEUKOCYTES, MONONUCLEAR; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; NUCLEOSIDES; POINT MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0038155280     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0300274     Document Type: Article

References (34)

1. (a) Lin, T.-S.; Guo, J.-Y.; Schinazi, R. F.; Chu, C. K.; Xiang, J.-N.; Prusoff, W. H. Synthesis and antiviral activity of various 3′-azido analogues of pyrimidine deoxyriboucleosides against human immunodeficiency virus (HIV-1, HTLV-III/LAV). J. Med. Chem. 1988, 31, 336-340.
2. (b) Mansour, T. S.; Tse, A.; Charron, M.; Hooker, E. U.; Ashman, C.; Cammack, N.; Cameron, J. M. Anti-HIV and anti-HBV activities of L-2′,3′-dideoxynucleoside analogs: ddC, 5FddC, 5-aza ddC and ddG. Med. Chem. Res. 1995, 5, 417-425.
3. (c) Schinazi, R. F.; Mellors, J.; Bazmi, H.; Diamond, S.; Garber, S.; Gallagher, K.; Geleziunas, R.; Klabe, R.; Pierce, M.; Rayner, M.; Wu, J.-T.; Zhang, H.; Hammond, J.; Bacheler, L.; Manion, D. J.; Otto, M. J.; Stuyver, L.; Trainor, G.; Liotta, D. C.; Erickson-Viitanen, S. DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants. Antimicrob. Agents Chemother. 2002, 46, 1394-1401.
4. (d) Jeong, L. S.; Schinazi, R. F.; Beach, J. W.; Kim, H. O.; Nampalli, S.; Shanmuganathan, K.; Alves, A. J.; McMillan, A.; Chu, C. K.; Mathis, R. Asymmetric synthesis and biological evaluation of β-L-(2R,5S)- and β-L-(2R,5R)-1,3-oxatholane-pyrimidine and purine nucleosides as potential anti-HIV agents. J. Med. Chem. 1993, 36, 181-195.
5. (e) Lin, T.-S.; Luo, M.-Z.; Liu, M.-C.; Zhu, Y.-L.; Gullen, E.; Dutschman, G. E.; Cheng, Y.-C. Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-β-L-cytidine (β-L-d4C) and 2′,3′-dideoxy-2′,3′-didehydro-β-L-5- fluorocytidine (β-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. J. Med. Chem. 1996, 39, 1757-1759.
6. (f) Lin, T.-S.; Luo, M.-Z.; Liu, M.-C.; Pai, S. B.; Dutschman, G. E.; Cheng, Y.-C. Antiviral activity of 2′,3′-dideoxy-β-L-5-fluorocytidine (β-L-FddC) and 2′,3′-dideoxy-β-L-cytidine (β-L-ddC) against hepatitis B virus and human immunodeficiency virus in vitro. Biochem. Pharmacol. 1994, 47, 171-174.
7. (a) Van Aerschot, A.; Herdewijn, P.; Balzarini, J.; Pauwels, R.; De Clercq, E. 3′-Fluoro-2′,3′-dideoxy-5-chlorouridine: Most selective anti-HIV-1 agent among a series of new 2′-and 3′-fluorinated 2′,3′-dideoxynucleoside analogues. J. Med. Chem. 1989, 32, 1743-1749.
8. (b) Lee, K.; Choi, Y.; Gullen, E.; Schlueter-Wirtz, S.; Schinazi, R. F.; Cheng, Y.-C.; Chu, C. K. Synthesis and anti-HIV and anti-HBV activities of 2′-fluoro-2′,3′-unsaturated L-nucleosides. J. Med. Chem. 1999, 42, 1320-1328.
9. (c) Lee, K.; Choi, Y.; Gumina, G.; Zhou, W.; Schinazi, R. F.; Chu, C. K. Structure-activity relationships of 2′-fluoro-2′,3′-unsaturated D-nucleosides as anti-HIV-1 agents. J. Med. Chem. 2002, 45, 1313-1320
10. (d) Chong, Y.; Choo, H.; Lee, S.; Choi, Y.; Schinazi, R. F.; Chu, C. K. Stereoselective synthesis and antiviral activities of D-2′,3′-didehydro-2′,3′-dideoxy-2′-fluoro-4 ′-thionucleosides. J. Med. Chem. 2002, 45, 4888-4898.
11. (a) Matthes, E.; Lehmann, C.; Von Janta-Lipinski, M.; Scholz, D. Inhibition of HIV-replication by 3′-fluoro-modified nucleosides with low cytotoxicity. Biochem. Biophys. Res. Commun. 1989, 165, 488-495.
12. (b) Van Aerschot, A.; Everaert, D.; Balzarini, J.; Augustyns, K.; Jie, L.; Janssen, G.; Peeters, O.; Blaton, N.; De Ranter, C.; De Clercq, E.; Herdewijn, P. Synthesis and anti-HIV evaluation of 2′,3′-dideoxyribo-5-chloropyrimidine analogues: Reduced toxicity of 5-chlorinated 2′,3′-dideoxynucleosides. J. Med. Chem. 1990, 33, 1833-1839.
13. (c) Herdewijn, P.; Pauwels, R.; Baba, M.; Balzarini, J.; De Clercq, E. Synthesis and anti-HIV activity of various 2′ and 3′-substituted 2′,3′-dideoxyadenosines: A structure-activity analysis. J. Med. Chem. 1987, 30, 2131-2137.
14. (d) Matthes, E.; Scholz, D.; Sydow, G.; Von Janta-Lipinski, M.; Rosenthal, H. A.; Langen, P. 3′-Fluorosubstituted deoxynucleosides as potential anti-AIDS drugs. Z. Klin. Med. 1990, 45, 1255-1258.
15. (e) Daluge, S. M.; Purifoy, D. J.; Savina, P. M.; St. Clair, M. H.; Parry, N. R.; Dev, I. K.; Novak, P.; Ayers, K. M.; Reardon, J. E.; Roberts, G. B.; Fyfe, J. A.; Blum, M. R.; Averett, D. R.; Dornsife, R. E.; Domin, B. A.; Ferone, R.; Lewis, D. A.; Krenitsky, T. A. 5-chloro-2′,3′-dideoxy-3′-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob. Agents Chemother. 1994, 38, 1590-1603.
16. Gumina, G.; Schinazi, R. F.; Chu, C. K. Synthesis and potent anti-HIV activity of L-3′-fluoro-2′,3′-unsaturated cytidine. Org. Lett. 2001, 3, 4177-4180.
17. Van Aerschot, A.; Herdewijn, jP.; Balzarini, J.; Pauwels, R.; De Clercq, E. 3′-Fluoro-2′,3′-dideoxy-5-chlorouridine-Most selective anti-HIV-1 agent among a series of new 2′-fluorinated and 3′-fluorinated 2′,3′-dideoxynucleoside analogues. J. Med. Chem. 1989, 32, 1743-1749.
18. Chong, Y.; Chu, C. K. Efficient synthesis of 2-deoxy-L-erythropentose (2-deoxy-L-ribose) from L-arabinose. Carbohyd. Res. 2002, 337, 397-402.
19. Schinazi, R. F.; Lloyd, R. M., Jr.; Nguyen, M.-H.; Cannon, D. L.; McMillan, A.; Ilksoy, N.; Chu, C. K.; Liotta, D. C.; Bazmi, H. Z.; Mellors, J. W. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 1993, 37, 875-881.
20. Tisdale, M.; Kemp, S. D.; Parry, N. R.; Larder, B. A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiactidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 5653-5656.
21. (a) Chong, Y.; Borroto-Esoda, K.; Furman, P. A.; Schinazi, R. F.; Chu, C. K. Molecular mechanism of DAPD/DXG against zidovudine- and lamivudine-drug resistant mutants: a molecular modeling approach. Antivir. Chem. Chemother. 2002, 13, 115-128.
22. (b) Lee, K.; Chu, C. K. Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents. Antimicrob. Agents Chemother. 2001, 45, 138-144.
23. Coates, J. A. V.; Camack, N.; Jenkinson, H. J.; Mutton, I. M.; Pearson, B. A.; Storer, R.; Cameron, J. M.; Penn, C. R. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit HIV replication in vitro. Antimicrob. Agents Chemother. 1992, 36, 202-205.
24. Kredich, N. M.; Hershfeld, M. S. In The Metabolic and Molecular Basis of Inherited Disease; Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Eds.; McGraw-Hill: New York, 1989; pp 1045-1075.
25. Marquez, V. E.; Tseng, C. K.-H.; Mitsuya, H.; Aoki, S.; Kelley, J. A.; Ford, H., Jr.; Roth, J. S.; Broder, S.; Johns, D. G.; Driscoll, J. S. Acid-stable 2′-fluoro purine dideoxynucleosides as active agents against HIV. J. Med. Chem. 1990, 33, 978-985.
26. (a) Shafiee, M.; Griffon, J.-F.; Gosselin, G.; Cambi, A.; Vincenzetti, S.; Vita, A.; Erikson, S.; Imbach, J.-L.; Maury, G. A comparison of the enantioselectivities of human deoxycytidine kinase and human cytidine deaminase. Biochem. Pharmacol. 1998, 56, 1237-1242.
27. (b) Dutschman, G. E.; Bridges, E. G.; Liu, S. H.; Gullen, E.; Guo, X.; Kukhanova, M.; Cheng, Y. C. Metabolism of 2′,3′-dideoxy-2′,3′-didehydro-β-L-(-)-5- fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus β-D-(+) nucleoside analogs in vitro. Antimicrob. Agents Chemother. 1998, 42, 1799-1804.
28. (c) Grove, K. L.; Guo, X.; Liu, S. H.; Gao, Z. L.; Chu, C. K.; Cheng, Y. C. Anticancer activity of β-L-dioxolane-cytidine, a novel nucleoside analog with the unnatural L-configuration. Cancer Res. 1995, 55, 3008-3011.
29. Huang, H.; Chopra, R.; Verdine, G. L.; Harrison, S. C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance. Science 1998, 282, 1669-1675.
30. (a) Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A 2nd generation force-field for the simulation of proteins, nucleic acids, and organic-molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
31. (b) See the website: http://www.amber.uscf.edu/amber/Questions/fluorine.html
32. Dunitz, J. D.; Taylor, R. Organic fluorine hardly ever accepts hydrogen bonds. Chem. Eur. J. 1997, 3, 89-98.
33. Kredich, N. M.; Hershfeld, M. S. In The Metabolic and Molecular Basis of Inherited Disease; Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Eds.; McGraw-Hill: New York, 1989; pp 1045-1075.
34. Belen'kii, S. M.; Schinazi, R. S. Multiple drug effect analysis with confidence interval. Antiviral. Res. 1994, 25, 1-11.